The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma
Abstract
:Simple Summary
Abstract
1. Introduction
2. SABR Rationale and Patient Selection in Localized RCC
2.1. Overview of Staging and Management Options
2.2. Societal Guidelines and Rationale for SABR in Localized RCC
2.3. Patient Evaluation Prior to SABR
3. Treatment of Primary RCC with SABR
3.1. Selection of Treatment Prescription and Normal Tissue Constraints
3.2. Informed Consent
3.3. Treatment Setup, Design, and Delivery
3.4. Treatment Response Assessment
4. Conclusions and Future Directions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Capitanio, U.; Bensalah, K.; Bex, A.; Boorjian, S.A.; Bray, F.; Coleman, J.; Gore, J.L.; Sun, M.; Wood, C.; Russo, P. Epidemiology of Renal Cell Carcinoma. Eur. Urol. 2019, 75, 74–84. [Google Scholar] [CrossRef]
- Ferlay, J.; Colombet, M.; Soerjomataram, I.; Dyba, T.; Randi, G.; Bettio, M.; Gavin, A.; Visser, O.; Bray, F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer 2018, 103, 356–387. [Google Scholar] [CrossRef] [PubMed]
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Deschavanne, P.J.; Fertil, B. A review of human cell radiosensitivity in vitro. Int. J. Radiat. Oncol. Biol. Phys. 1996, 34, 251–266. [Google Scholar] [CrossRef]
- Ning, S.; Trisler, K.; Wessels, B.W.; Knox, S.J. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 1997, 80, 2519–2528. [Google Scholar] [CrossRef]
- DiBiase, S.J.; Valicenti, R.K.; Schultz, D.; Xie, Y.; Gomella, L.G.; Corn, B.W. Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: Support for dose escalation based on a biological model. J. Urol. 1997, 158, 746–749. [Google Scholar] [CrossRef] [PubMed]
- Onufrey, V.; Mohiuddin, M. Radiation therapy in the treatment of metastatic renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1985, 11, 2007–2009. [Google Scholar] [CrossRef] [PubMed]
- Fowler, J.F.; Tome, W.A.; Fenwick, J.D.; Mehta, M.P. A challenge to traditional radiation oncology. Int. J. Radiat. Oncol. Biol. Phys. 2004, 60, 1241–1256. [Google Scholar] [CrossRef] [PubMed]
- Benedict, S.H.; Yenice, K.M.; Followill, D.; Galvin, J.M.; Hinson, W.; Kavanagh, B.; Keall, P.; Lovelock, M.; Meeks, S.; Papiez, L.; et al. Stereotactic body radiation therapy: The report of AAPM Task Group 101. Med. Phys. 2010, 37, 4078–4101. [Google Scholar] [CrossRef] [Green Version]
- Correa, R.J.M.; Louie, A.V.; Zaorsky, N.G.; Lehrer, E.J.; Ellis, R.; Ponsky, L.; Kaplan, I.; Mahadevan, A.; Chu, W.; Swaminath, A.; et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur. Urol. Focus 2019, 5, 958–969. [Google Scholar] [CrossRef]
- Hannan, R.; McLaughlin, M.F.; Pop, L.M.; Pedrosa, I.; Kapur, P.; Garant, A.; Ahn, C.; Christie, A.; Zhu, J.; Wang, T.; et al. Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer. Eur. Urol. 2023. [Google Scholar] [CrossRef]
- Grubb, W.R.; Ponsky, L.; Lo, S.S.; Kharouta, M.; Traughber, B.; Sandstrom, K.; MacLennan, G.T.; Shankar, E.; Gupta, S.; Machtay, M.; et al. Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma. Radiother. Oncol. 2021, 155, 138–143. [Google Scholar] [CrossRef] [PubMed]
- Ponsky, L.; Lo, S.S.; Zhang, Y.; Schluchter, M.; Liu, Y.; Patel, R.; Abouassaly, R.; Welford, S.; Gulani, V.; Haaga, J.R.; et al. Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma. Radiother. Oncol. 2015, 117, 183–187. [Google Scholar] [CrossRef] [PubMed]
- Glicksman, R.M.; Cheung, P.; Korol, R.; Niglas, M.; Nusrat, H.; Erler, D.; Vesprini, D.; Swaminath, A.; Davidson, M.; Zhang, L.; et al. Stereotactic Body Radiotherapy for Renal Cell Carcinoma: Oncological and Renal Function Outcomes. Clin. Oncol. 2023, 35, 20–28. [Google Scholar] [CrossRef]
- Sun, M.R.; Brook, A.; Powell, M.F.; Kaliannan, K.; Wagner, A.A.; Kaplan, I.D.; Pedrosa, I. Effect of Stereotactic Body Radiotherapy on the Growth Kinetics and Enhancement Pattern of Primary Renal Tumors. AJR Am. J. Roentgenol. 2016, 206, 544–553. [Google Scholar] [CrossRef]
- Siva, S.; Ali, M.; Correa, R.J.M.; Muacevic, A.; Ponsky, L.; Ellis, R.J.; Lo, S.S.; Onishi, H.; Swaminath, A.; McLaughlin, M.; et al. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: An individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol. 2022, 23, 1508–1516. [Google Scholar] [CrossRef]
- Abou Elkassem, A.M.; Lo, S.S.; Gunn, A.J.; Shuch, B.M.; Dewitt-Foy, M.E.; Abouassaly, R.; Vaidya, S.S.; Clark, J.I.; Louie, A.V.; Siva, S.; et al. Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective. Radiographics 2021, 41, 1387–1407. [Google Scholar] [CrossRef]
- Vogel, C.; Ziegelmuller, B.; Ljungberg, B.; Bensalah, K.; Bex, A.; Canfield, S.; Giles, R.H.; Hora, M.; Kuczyk, M.A.; Merseburger, A.S.; et al. Imaging in Suspected Renal-Cell Carcinoma: Systematic Review. Clin. Genitourin. Cancer 2019, 17, e345–e355. [Google Scholar] [CrossRef]
- Delahunt, B.; Eble, J.N.; Samaratunga, H.; Thunders, M.; Yaxley, J.W.; Egevad, L. Staging of renal cell carcinoma: Current progress and potential advances. Pathology 2021, 53, 120–128. [Google Scholar] [CrossRef] [PubMed]
- NCCN. National Comprehensive Cancer Network: Kidney Cancer (Version 4.2023). 2023. Available online: https://www.nccn.org (accessed on 15 June 2023).
- Ljungberg, B.; Albiges, L.; Abu-Ghanem, Y.; Bedke, J.; Capitanio, U.; Dabestani, S.; Fernandez-Pello, S.; Giles, R.H.; Hofmann, F.; Hora, M.; et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur. Urol. 2022, 82, 399–410. [Google Scholar] [CrossRef] [PubMed]
- Finelli, A.; Ismaila, N.; Bro, B.; Durack, J.; Eggener, S.; Evans, A.; Gill, I.; Graham, D.; Huang, W.; Jewett, M.A.; et al. Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2017, 35, 668–680. [Google Scholar] [CrossRef] [PubMed]
- Campbell, S.C.; Clark, P.E.; Chang, S.S.; Karam, J.A.; Souter, L.; Uzzo, R.G. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. J. Urol. 2021, 206, 199–208. [Google Scholar] [CrossRef]
- Ray, S.; Cheaib, J.G.; Pierorazio, P.M. Active Surveillance for Small Renal Masses. Rev. Urol. 2020, 22, 9–16. [Google Scholar] [PubMed]
- Patel, H.D.; Kates, M.; Pierorazio, P.M.; Gorin, M.A.; Jayram, G.; Ball, M.W.; Hyams, E.S.; Allaf, M.E. Comorbidities and causes of death in the management of localized T1a kidney cancer. Int. J. Urol. 2014, 21, 1086–1092. [Google Scholar] [CrossRef] [Green Version]
- Lane, B.R.; Abouassaly, R.; Gao, T.; Weight, C.J.; Hernandez, A.V.; Larson, B.T.; Kaouk, J.H.; Gill, I.S.; Campbell, S.C. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 2010, 116, 3119–3126. [Google Scholar] [CrossRef]
- Mir, M.C.; Capitanio, U.; Bertolo, R.; Ouzaid, I.; Salagierski, M.; Kriegmair, M.; Volpe, A.; Jewett, M.A.S.; Kutikov, A.; Pierorazio, P.M.; et al. Role of Active Surveillance for Localized Small Renal Masses. Eur. Urol. Oncol. 2018, 1, 177–187. [Google Scholar] [CrossRef]
- Smaldone, M.C.; Kutikov, A.; Egleston, B.L.; Canter, D.J.; Viterbo, R.; Chen, D.Y.; Jewett, M.A.; Greenberg, R.E.; Uzzo, R.G. Small renal masses progressing to metastases under active surveillance: A systematic review and pooled analysis. Cancer 2012, 118, 997–1006. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grant, S.R.; Lei, X.; Hess, K.R.; Smith, G.L.; Matin, S.F.; Wood, C.G.; Nguyen, Q.; Frank, S.J.; Anscher, M.S.; Smith, B.D.; et al. Stereotactic Body Radiation Therapy for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison with Surgery, Tumor Ablation, and Observation. Adv. Radiat. Oncol. 2020, 5, 495–502. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Finelli, A.; Cheung, D.C.; Al-Matar, A.; Evans, A.J.; Morash, C.G.; Pautler, S.E.; Siemens, D.R.; Tanguay, S.; Rendon, R.A.; Gleave, M.E.; et al. Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort. Eur. Urol. 2020, 78, 460–467. [Google Scholar] [CrossRef] [PubMed]
- Psutka, S.P.; Gulati, R.; Jewett, M.A.S.; Fadaak, K.; Finelli, A.; Legere, L.; Morgan, T.M.; Pierorazio, P.M.; Allaf, M.E.; Herrin, J.; et al. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. Eur. Urol. 2022, 81, 576–585. [Google Scholar] [CrossRef] [PubMed]
- El Dib, R.; Touma, N.J.; Kapoor, A. Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: A meta-analysis of case series studies. BJU Int. 2012, 110, 510–516. [Google Scholar] [CrossRef] [PubMed]
- Abdelsalam, M.E.; Awad, A.; Baiomy, A.; Irwin, D.; Karam, J.A.; Matin, S.F.; Sheth, R.A.; Habibollahi, P.; Odisio, B.C.; Lu, T.; et al. Outcomes of Radiofrequency Ablation for Solitary T1a Renal Cell Carcinoma: A 20-Year Tertiary Cancer Center Experience. Cancers 2023, 15, 909. [Google Scholar] [CrossRef]
- Nielsen, T.K.; Vedel, P.F.; Borgbjerg, J.; Andersen, G.; Borre, M. Renal cryoablation: Five- and 10-year survival outcomes in patients with biopsy-proven renal cell carcinoma. Scand. J. Urol. 2020, 54, 408–412. [Google Scholar] [CrossRef] [PubMed]
- Wah, T.M.; Irving, H.C.; Gregory, W.; Cartledge, J.; Joyce, A.D.; Selby, P.J. Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): Experience in 200 tumours. BJU Int. 2014, 113, 416–428. [Google Scholar] [CrossRef] [Green Version]
- Choi, S.H.; Kim, J.W.; Kim, J.H.; Kim, K.W. Efficacy and Safety of Microwave Ablation for Malignant Renal Tumors: An Updated Systematic Review and Meta-Analysis of the Literature Since 2012. Korean J. Radiol. 2018, 19, 938–949. [Google Scholar] [CrossRef] [PubMed]
- Abu-Ghanem, Y.; Fernandez-Pello, S.; Bex, A.; Ljungberg, B.; Albiges, L.; Dabestani, S.; Giles, R.H.; Hofmann, F.; Hora, M.; Kuczyk, M.A.; et al. Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel. Eur. Urol. Oncol. 2020, 3, 433–452. [Google Scholar] [CrossRef] [PubMed]
- Kanesvaran, R.; Porta, C.; Wong, A.; Powles, T.; Ng, Q.S.; Schmidinger, M.; Ye, D.; Malhotra, H.; Miura, Y.; Lee, J.L.; et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. ESMO Open 2021, 6, 100304. [Google Scholar] [CrossRef] [PubMed]
- Prins, F.M.; Kerkmeijer, L.G.W.; Pronk, A.A.; Vonken, E.P.A.; Meijer, R.P.; Bex, A.; Barendrecht, M.M. Renal Cell Carcinoma: Alternative Nephron-Sparing Treatment Options for Small Renal Masses, a Systematic Review. J. Endourol. 2017, 31, 963–975. [Google Scholar] [CrossRef] [PubMed]
- Escudier, B.; Porta, C.; Schmidinger, M.; Rioux-Leclercq, N.; Bex, A.; Khoo, V.; Grunwald, V.; Gillessen, S.; Horwich, A. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2019, 30, 706–720. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Siva, S.; Pham, D.; Kron, T.; Bressel, M.; Lam, J.; Tan, T.H.; Chesson, B.; Shaw, M.; Chander, S.; Gill, S.; et al. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: A prospective clinical trial. BJU Int. 2017, 120, 623–630. [Google Scholar] [CrossRef] [Green Version]
- Juarez, J.E.; Romero, T.; Mantz, C.A.; Pepin, A.; Aghdam, N.; Suy, S.; Steinberg, M.L.; Levin-Epstein, R.G.; Nickols, N.G.; Kaplan, I.D.; et al. Toxicity after Stereotactic Body Radiation Therapy for Prostate Cancer in Patients with Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series. Adv. Radiat. Oncol. 2021, 6, 100759. [Google Scholar] [CrossRef] [PubMed]
- Shaikh, P.M.; Singh, S.A.; Alite, F.; Vargo, J.A.; Emami, B.; Wu, M.J.; Jacobson, G.; Bakalov, V.; Small, W., Jr.; Dahshan, B.; et al. Radiation Toxicity in Patients with Collagen Vascular Disease: A Meta-Analysis of Case-Control Studies. Int. J. Radiat. Oncol. Biol. Phys. 2021, 111, 1214–1226. [Google Scholar] [CrossRef] [PubMed]
- Kroeze, S.G.C.; Pavic, M.; Stellamans, K.; Lievens, Y.; Becherini, C.; Scorsetti, M.; Alongi, F.; Ricardi, U.; Jereczek-Fossa, B.A.; Westhoff, P.; et al. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: Systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol. 2023, 24, e121–e132. [Google Scholar] [CrossRef] [PubMed]
- Shuch, B.; Vourganti, S.; Ricketts, C.J.; Middleton, L.; Peterson, J.; Merino, M.J.; Metwalli, A.R.; Srinivasan, R.; Linehan, W.M. Defining early-onset kidney cancer: Implications for germline and somatic mutation testing and clinical management. J. Clin. Oncol. 2014, 32, 431–437. [Google Scholar] [CrossRef] [Green Version]
- Kirste, S.; Ruhle, A.; Zschiedrich, S.; Schultze-Seemann, W.; Jilg, C.A.; Neumann-Haefelin, E.; Lo, S.S.; Grosu, A.L.; Kim, E. Stereotactic Body Radiotherapy for Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease-Results of a Prospective Trial. Cancers 2022, 14, 5069. [Google Scholar] [CrossRef]
- Stevens, P.E.; Levin, A.; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med. 2013, 158, 825–830. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Matsushita, K.; Mahmoodi, B.K.; Woodward, M.; Emberson, J.R.; Jafar, T.H.; Jee, S.H.; Polkinghorne, K.R.; Shankar, A.; Smith, D.H.; Tonelli, M.; et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012, 307, 1941–1951. [Google Scholar] [CrossRef] [Green Version]
- Correa, R.J.M.; Louie, A.V.; Staehler, M.; Warner, A.; Gandhidasan, S.; Ponsky, L.; Ellis, R.; Kaplan, I.; Mahadevan, A.; Chu, W.; et al. Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK. J. Urol. 2019, 201, 1097–1104. [Google Scholar] [CrossRef] [PubMed]
- Siva, S.; Jackson, P.; Kron, T.; Bressel, M.; Lau, E.; Hofman, M.; Shaw, M.; Chander, S.; Pham, D.; Lawrentschuk, N.; et al. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose-response relationship. Radiother. Oncol. 2016, 118, 540–546. [Google Scholar] [CrossRef] [PubMed]
- Siva, S.; Correa, R.J.M.; Warner, A.; Staehler, M.; Ellis, R.J.; Ponsky, L.; Kaplan, I.D.; Mahadevan, A.; Chu, W.; Gandhidasan, S.; et al. Stereotactic Ablative Radiotherapy for >/=T1b Primary Renal Cell Carcinoma: A Report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Int. J. Radiat. Oncol. Biol. Phys. 2020, 108, 941–949. [Google Scholar] [CrossRef] [PubMed]
- Siva, S.; Chesson, B.; Bressel, M.; Pryor, D.; Higgs, B.; Reynolds, H.M.; Hardcastle, N.; Montgomery, R.; Vanneste, B.; Khoo, V.; et al. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney—FASTRACK II. BMC Cancer 2018, 18, 1030. [Google Scholar] [CrossRef] [Green Version]
- Grelier, L.; Baboudjian, M.; Gondran-Tellier, B.; Couderc, A.L.; McManus, R.; Deville, J.L.; Carballeira, A.; Delonca, R.; Delaporte, V.; Padovani, L.; et al. Stereotactic Body Radiotherapy for Frail Patients with Primary Renal Cell Carcinoma: Preliminary Results after 4 Years of Experience. Cancers 2021, 13, 3129. [Google Scholar] [CrossRef]
- Correa, R.J.M.; Rodrigues, G.B.; Chen, H.; Warner, A.; Ahmad, B.; Louie, A.V. Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors: A Retrospective Case Series Evaluating Clinical Outcomes, Toxicity, and Technical Considerations. Am. J. Clin. Oncol. 2018, 41, 568–575. [Google Scholar] [CrossRef]
- Haddad, A.Q.; Leibovich, B.C.; Abel, E.J.; Luo, J.H.; Krabbe, L.M.; Thompson, R.H.; Heckman, J.E.; Merrill, M.M.; Gayed, B.A.; Sagalowsky, A.I.; et al. Preoperative multivariable prognostic models for prediction of survival and major complications following surgical resection of renal cell carcinoma with suprahepatic caval tumor thrombus. Urol. Oncol. 2015, 33, 388.e1–388.e9. [Google Scholar] [CrossRef]
- Freifeld, Y.; Pedrosa, I.; McLaughlin, M.; Correa, R.M.; Louie, A.V.; Maldonado, J.A.; Tang, C.; Kadow, B.; Kutikov, A.; Uzzo, R.G.; et al. Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus. Urol. Oncol. 2022, 40, 166.e9–166.e13. [Google Scholar] [CrossRef]
- Margulis, V.; Freifeld, Y.; Pop, L.M.; Manna, S.; Kapur, P.; Pedrosa, I.; Christie, A.; Mohamad, O.; Mannala, S.; Singla, N.; et al. Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus-Safety Lead-in Results of a Phase 2 Trial. Int. J. Radiat. Oncol. Biol. Phys. 2021, 110, 1135–1142. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Liu, Z.; Peng, R.; Xiao, R.; Wang, J.; Wang, H.; Ma, L. Preoperative stereotactic body radiotherapy combined with surgical treatment for renal cell carcinoma and inferior vena cava tumour thrombus: Study protocol for a single-arm cohort trial. BMJ Open 2022, 12, e055364. [Google Scholar] [CrossRef]
- Tran, K.T.; Chevli, N.C.; Messer, J.A.; Haque, W.; Farach, A.M.; Satkunasivam, R.; Zhang, J.; Darcourt, J.; Lo, S.S.; Siva, S.; et al. Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer. Clin. Transl. Radiat. Oncol. 2023, 39, 100592. [Google Scholar] [CrossRef] [PubMed]
- Lapierre, A.; Badet, L.; Rouviere, O.; Crehange, G.; Berthiller, J.; Paparel, P.; Chapet, O. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Cancer: 24-Month Results of the RSR1 Phase 1 Dose Escalation Study. Pract. Radiat. Oncol. 2023, 13, e73–e79. [Google Scholar] [CrossRef] [PubMed]
- Siva, S.; Ellis, R.J.; Ponsky, L.; Teh, B.S.; Mahadevan, A.; Muacevic, A.; Staehler, M.; Onishi, H.; Wersall, P.; Nomiya, T.; et al. Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncol. 2016, 12, 637–645. [Google Scholar] [CrossRef] [PubMed]
- Bae, S.H.; Kim, M.S.; Kim, S.Y.; Jang, W.I.; Cho, C.K.; Yoo, H.J.; Kim, K.B.; Lee, D.H.; Han, C.J.; Yang, K.Y.; et al. Severe intestinal toxicity after stereotactic ablative radiotherapy for abdominopelvic malignancies. Int. J. Colorectal Dis. 2013, 28, 1707–1713. [Google Scholar] [CrossRef] [PubMed]
- Khriguian, J.; Patrocinio, H.; Andonian, S.; Aprikian, A.; Kassouf, W.; Tanguay, S.; Cury, F.L. Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma. Pract. Radiat. Oncol. 2022, 12, e34–e39. [Google Scholar] [CrossRef] [PubMed]
- Staehler, M.; Bader, M.; Schlenker, B.; Casuscelli, J.; Karl, A.; Roosen, A.; Stief, C.G.; Bex, A.; Wowra, B.; Muacevic, A. Single fraction radiosurgery for the treatment of renal tumors. J. Urol. 2015, 193, 771–775. [Google Scholar] [CrossRef] [PubMed]
- Timmerman, R. A Story of Hypofractionation and the Table on the Wall. Int. J. Radiat. Oncol. Biol. Phys. 2022, 112, 4–21. [Google Scholar] [CrossRef]
- Hilleary, L.A.; Wratten, C.; Siva, S.; Hilleary, J.; Martin, J.M. Intratumoural renal cell carcinoma haemorrhage following stereotactic radiotherapy: A case report. BMC Cancer 2019, 19, 671. [Google Scholar] [CrossRef] [Green Version]
- Tetar, S.U.; Bohoudi, O.; Senan, S.; Palacios, M.A.; Oei, S.S.; Wel, A.M.V.; Slotman, B.J.; Moorselaar, R.; Lagerwaard, F.J.; Bruynzeel, A.M.E. The Role of Daily Adaptive Stereotactic MR-Guided Radiotherapy for Renal Cell Cancer. Cancers 2020, 12, 2763. [Google Scholar] [CrossRef]
- Liu, Y. The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations. Front. Oncol. 2016, 6, 201. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Muselaers, S.; Erdem, S.; Bertolo, R.; Ingels, A.; Kara, O.; Pavan, N.; Roussel, E.; Pecoraro, A.; Marchioni, M.; Carbonara, U.; et al. PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature. J. Clin. Med. 2022, 11, 1829. [Google Scholar] [CrossRef] [PubMed]
- Chevli, N.; Chiang, S.B.; Farach, A.M.; Haque, W.; Satkunasivam, R.; Bernicker, E.H.; Pino, R.; Butler, E.B.; Teh, B.S. DMSA-SPECT: A Novel Approach to Nephron Sparing SBRT for Renal Cell Carcinoma. Adv. Radiat. Oncol. 2021, 6, 100719. [Google Scholar] [CrossRef]
- Senger, C.; Conti, A.; Kluge, A.; Pasemann, D.; Kufeld, M.; Acker, G.; Lukas, M.; Grun, A.; Kalinauskaite, G.; Budach, V.; et al. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function. BMC Urol. 2019, 19, 96. [Google Scholar] [CrossRef] [Green Version]
- Gaudreault, M.; Siva, S.; Kron, T.; Hardcastle, N. Reducing the impact on renal function of kidney SABR through management of respiratory motion. Phys. Med. 2021, 89, 72–79. [Google Scholar] [CrossRef]
- Funayama, S.; Onishi, H.; Kuriyama, K.; Komiyama, T.; Marino, K.; Araya, M.; Saito, R.; Aoki, S.; Maehata, Y.; Nonaka, H.; et al. Renal Cancer is Not Radioresistant: Slowly but Continuing Shrinkage of the Tumor after Stereotactic Body Radiation Therapy. Technol. Cancer Res. Treat. 2019, 18, 1533033818822329. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Campbell, S.C.; Uzzo, R.G.; Karam, J.A.; Chang, S.S.; Clark, P.E.; Souter, L. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II. J. Urol. 2021, 206, 209–218. [Google Scholar] [CrossRef]
- Mittlmeier, L.M.; Unterrainer, M.; Rodler, S.; Todica, A.; Albert, N.L.; Burgard, C.; Cyran, C.C.; Kunz, W.G.; Ricke, J.; Bartenstein, P.; et al. (18)F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: Preliminary results. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 2031–2037. [Google Scholar] [CrossRef] [PubMed]
- Correa, R.J.M.; Appu, S.; Siva, S. Stereotactic Radiotherapy for Renal Cell Carcinoma: The Fallacy of (False) Positive Post-treatment Biopsy? Eur. Urol. 2023, in press. [Google Scholar] [CrossRef] [PubMed]
- Francini, E.; Fanelli, G.N.; Pederzoli, F.; Spisak, S.; Minonne, E.; Raffo, M.; Pakula, H.; Tisza, V.; Scatena, C.; Naccarato, A.G.; et al. Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine. Cancers 2022, 14, 4359. [Google Scholar] [CrossRef] [PubMed]
- Nuzzo, P.V.; Berchuck, J.E.; Korthauer, K.; Spisak, S.; Nassar, A.H.; Abou Alaiwi, S.; Chakravarthy, A.; Shen, S.Y.; Bakouny, Z.; Boccardo, F.; et al. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat. Med. 2020, 26, 1041–1043. [Google Scholar] [CrossRef] [PubMed]
Organ | One Fraction | Three Fractions | Five Fractions |
---|---|---|---|
D0.035cc < 22 Gy a or 26 Gy b | D0.035cc < 30 Gy a,b | D0.035cc < 35 Gy a or < 29 Gy d | |
Small bowel/duodenum | D5cc < 17.4 Gy a or < 22.5 Gy b | D5cc < 22.5 Gy a or D30cc < 12.5 Gy b | D5cc < 26.5 Gy a |
Maximum dose to full bowel wall circumference ≤ 12.5 Gy b | |||
Large bowel | D0.035cc < 31 Gy a or D1.5cc ALARA, aim for < 26 Gy b | D0.035cc < 45 Gya or D1.5cc ALARA, aim for <42 Gy b | D0.035cc <52.5 Gy a or <29 Gy d |
Stomach | D0.035cc < 22 Gy a or D1.5cc < 15.4 Gy b | D0.035cc < 30 Gy a,b | D0.035cc <35 Gy a or <29 Gy d |
Liver | D700cc < 11.6 Gy a | D700cc < 15 Gy b or <17.7 Gy a | D700cc <19.6 Gy a or D50% < 25 Gy d |
Ipsilateral kidney–ITV | ALARA, minimize volume of >50% IDL b | ALARA, minimize volume of >50% IDL b | D60% < 15 Gy d |
Contralateral kidney | V10Gy ≤ 33% b | V10Gy ≤ 33% b | D100% < 11 Gy d |
Ureter | D0.035 cm3 < 35 Gy a | D0.035 cm3 < 40 Gy a | D0.035 cm3 < 45 Gy a |
Spinal canal | D0.035 cm3 < 12 Gy c | D0.035 cm3 < 18 Gy c | D0.035 cm3 < 27.5 Gy c |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Barbour, A.B.; Kirste, S.; Grosu, A.-L.; Siva, S.; Louie, A.V.; Onishi, H.; Swaminath, A.; Teh, B.S.; Psutka, S.P.; Weg, E.S.; et al. The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma. Cancers 2023, 15, 3672. https://doi.org/10.3390/cancers15143672
Barbour AB, Kirste S, Grosu A-L, Siva S, Louie AV, Onishi H, Swaminath A, Teh BS, Psutka SP, Weg ES, et al. The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma. Cancers. 2023; 15(14):3672. https://doi.org/10.3390/cancers15143672
Chicago/Turabian StyleBarbour, Andrew B., Simon Kirste, Anca-Liga Grosu, Shankar Siva, Alexander V. Louie, Hiroshi Onishi, Anand Swaminath, Bin S. Teh, Sarah P. Psutka, Emily S. Weg, and et al. 2023. "The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma" Cancers 15, no. 14: 3672. https://doi.org/10.3390/cancers15143672